Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2018

01-10-2018 | Research Article

Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens

Authors: XiangQing Song, MingHui Long

Published in: International Journal of Clinical Pharmacy | Issue 5/2018

Login to get access

Abstract

Background Continual evolution of resistance among bacteria against methods of surgical prophylaxis may make currently used beta-lactam regimens inadequate. Objective To re-evaluate beta-lactam regimens in surgical prophylaxis. Setting A pharmacodynamic Monte Carlo simulation (MCS) model based on a number of patients in China. Methods Pharmacodynamic profiling using Monte Carlo simulation up to 4 hours postinfusion was conducted for standard-dose, short-term (0.5 h) and prolonged (2 to 4 h) infusions of ampicillin, cefazolin, cefotaxime, cefoxitin, cefuroxime, ertapenem, and piperacillin/tazobactam in adult patients with normal renal function. Microbiological data were incorporated. Cumulative fraction of response (CFR) was determined for each regimen against populations of S. aureus, coagulase-negative staphylococci and E. coli. The optimal CFR was defined as ≥ 90% response. Main Outcome Measure Cumulative fractions of response of pharmacodynamic target attainment. Results During the first 2 hours postinfusion, piperacillin/tazobactam 3.375 g exhibited consistently optimal cumulative fractions against S. aureus, CoNS and E. coli. Ampicillin 2 g (2 h) also displayed optimal CFRs for S. aureus and E. coli but not for coagulase-negative staphylococci. Cefoxitin 2 g didnot achieve any optimal CFRs, even via 2-h prolonged infusion (maximum 72.8% CFR for S. aureus and 64.5% CFR for E. coli). Cefazolin 2 g (4 h) and cefuroxime 1.5 g (4 h) provided desired CFRs across 4 h postinfusion for S. aureus but provided poor CFRs for coagulase-negative staphylococci and E. coli. Only ertapenem 1 g for E. coli and S. aureus and cefotaxime 1 g for E. coli consistently yielded ≥ 90% CFRs for 4 hour postinfusion. Conclusions Certain dosing regimens may warrant adjustment for improved prevention efficiency and enhanced empirical antibiotic regimens for surgical prophylaxis.
Literature
2.
go back to reference Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152:784–91.CrossRef Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152:784–91.CrossRef
4.
go back to reference Haripriya A. Antibiotic prophylaxis in cataract surgery–an evidence-based approach. Indian J Ophthalmol. 2017;65:1390–5.CrossRef Haripriya A. Antibiotic prophylaxis in cataract surgery–an evidence-based approach. Indian J Ophthalmol. 2017;65:1390–5.CrossRef
5.
go back to reference Zapata-Copete J, Aguilera-Mosquera S, García-Perdomo HA. Antibiotic prophylaxis in breast reduction surgery: a systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2017;70:1689–95.CrossRef Zapata-Copete J, Aguilera-Mosquera S, García-Perdomo HA. Antibiotic prophylaxis in breast reduction surgery: a systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2017;70:1689–95.CrossRef
6.
go back to reference Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195–283.CrossRef Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70:195–283.CrossRef
7.
go back to reference McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.CrossRef McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.CrossRef
8.
go back to reference Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016;72:839–48.CrossRef Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol. 2016;72:839–48.CrossRef
9.
go back to reference Johnson DP. Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee. J Bone Jt Surg Br. 1987;69:787–9.CrossRef Johnson DP. Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee. J Bone Jt Surg Br. 1987;69:787–9.CrossRef
10.
go back to reference Koomanachai P, Yungyuen T, Disthaporn P, Kiratisin P, Nicolau DP. Application of pharmacodynamic profiling for the selection of optimal β-lactam regimens in a large university hospital. Int J Infect Dis. 2016;46:22–6.CrossRef Koomanachai P, Yungyuen T, Disthaporn P, Kiratisin P, Nicolau DP. Application of pharmacodynamic profiling for the selection of optimal β-lactam regimens in a large university hospital. Int J Infect Dis. 2016;46:22–6.CrossRef
11.
go back to reference Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther. 2010;32:766–79.CrossRef Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther. 2010;32:766–79.CrossRef
13.
go back to reference Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol. 1999;20:250–278; quiz 279–280.CrossRef Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol. 1999;20:250–278; quiz 279–280.CrossRef
17.
go back to reference Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; CLSI supplement M100.Document M100-S27. Wayne: CLSI; 2017. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; CLSI supplement M100.Document M100-S27. Wayne: CLSI; 2017.
18.
go back to reference Moine P, Mueller SW, Schoen JA, Rothchild KB, Fish DN. Pharmacokinetic and pharmacodynamic evaluation of a weight-based dosing regimen of cefoxitin for perioperative surgical prophylaxis in obese and morbidly obese patients. Antimicrob Agents Chemother. 2016;60:5885–93.CrossRef Moine P, Mueller SW, Schoen JA, Rothchild KB, Fish DN. Pharmacokinetic and pharmacodynamic evaluation of a weight-based dosing regimen of cefoxitin for perioperative surgical prophylaxis in obese and morbidly obese patients. Antimicrob Agents Chemother. 2016;60:5885–93.CrossRef
19.
go back to reference Suffoletta TJ, Jennings HR, Oh JJ, Stephens D, Poe KL. Continuous versus intermittent infusion of prophylactic cefoxitin after colorectal surgery: a pilot study. Pharmacotherapy. 2008;28:1133–9.CrossRef Suffoletta TJ, Jennings HR, Oh JJ, Stephens D, Poe KL. Continuous versus intermittent infusion of prophylactic cefoxitin after colorectal surgery: a pilot study. Pharmacotherapy. 2008;28:1133–9.CrossRef
20.
go back to reference Ferraz ÁAB, de Siqueira LT, Campos JM, de Araújo GC, Martins Filho ED, Ferraz EM. Antibiotic prophylaxis in bariatric surgery: a continuous infusion of cefazolin versus ampicillin/sulbactam and ertapenem. Arq Gastroenterol. 2015;52:83–7.CrossRef Ferraz ÁAB, de Siqueira LT, Campos JM, de Araújo GC, Martins Filho ED, Ferraz EM. Antibiotic prophylaxis in bariatric surgery: a continuous infusion of cefazolin versus ampicillin/sulbactam and ertapenem. Arq Gastroenterol. 2015;52:83–7.CrossRef
21.
go back to reference Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, et al. Pharmacodynamic target attainment of seven antimicrobials against gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007;30:452–7.CrossRef Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, et al. Pharmacodynamic target attainment of seven antimicrobials against gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007;30:452–7.CrossRef
22.
go back to reference Wildfeuer A, Müller V, Springsklee M, Sonntag HG. Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery. Antimicrob Agents Chemother. 1991;35:1772–6.CrossRef Wildfeuer A, Müller V, Springsklee M, Sonntag HG. Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery. Antimicrob Agents Chemother. 1991;35:1772–6.CrossRef
23.
go back to reference Brown RM, Wise R, Andrews JM, Hancox J. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother. 1982;21:565–7.CrossRef Brown RM, Wise R, Andrews JM, Hancox J. Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother. 1982;21:565–7.CrossRef
24.
go back to reference Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother. 2013;57:5679–83.CrossRef Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother. 2013;57:5679–83.CrossRef
25.
go back to reference Zhang Y, Wang F, Zhang J, Shi Y, Wang Z, Dai Z. Clinical pharmacokinetics research and dosage regimen of cephalosporins. Chin J Infect. 1995;13:195–8. Zhang Y, Wang F, Zhang J, Shi Y, Wang Z, Dai Z. Clinical pharmacokinetics research and dosage regimen of cephalosporins. Chin J Infect. 1995;13:195–8.
26.
go back to reference Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA, et al. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother. 2004;54:199–205.CrossRef Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA, et al. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother. 2004;54:199–205.CrossRef
27.
go back to reference van Zanten ARH, Oudijk M, Nohlmans-Paulssen MKE, van der Meer YG, Girbes ARJ, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol. 2007;63:100–9.CrossRef van Zanten ARH, Oudijk M, Nohlmans-Paulssen MKE, van der Meer YG, Girbes ARJ, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol. 2007;63:100–9.CrossRef
28.
go back to reference Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob Agents Chemother. 1989;33:356–61.CrossRef Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob Agents Chemother. 1989;33:356–61.CrossRef
29.
30.
go back to reference Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother. 1976;9:741–7.CrossRef Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother. 1976;9:741–7.CrossRef
31.
go back to reference Pletz MWR, Rau M, Bulitta J, De Roux A, Burkhardt O, Kruse G, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother. 2004;48:3765–72.CrossRef Pletz MWR, Rau M, Bulitta J, De Roux A, Burkhardt O, Kruse G, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother. 2004;48:3765–72.CrossRef
32.
go back to reference Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother. 2006;58:632–6.CrossRef Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother. 2006;58:632–6.CrossRef
33.
go back to reference Kinzig M, Sörgel F, Brismar B, Nord CE. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992;36:1997–2004.CrossRef Kinzig M, Sörgel F, Brismar B, Nord CE. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992;36:1997–2004.CrossRef
34.
go back to reference Landersdorfer CB, Bulitta JB, Kirkpatrick CMJ, Kinzig M, Holzgrabe U, Drusano GL, et al. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother. 2012;56:5715–23.CrossRef Landersdorfer CB, Bulitta JB, Kirkpatrick CMJ, Kinzig M, Holzgrabe U, Drusano GL, et al. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother. 2012;56:5715–23.CrossRef
35.
go back to reference Price KE, McGregor DN. Basic design of beta-lactam antibiotics–cephalosporins. Scand J Infect Dis Suppl. 1984;42:50–63.PubMed Price KE, McGregor DN. Basic design of beta-lactam antibiotics–cephalosporins. Scand J Infect Dis Suppl. 1984;42:50–63.PubMed
36.
go back to reference Bergan T. Pharmacokinetics of beta-lactam antibiotics. Scand J Infect Dis Suppl. 1984;42:83–98.PubMed Bergan T. Pharmacokinetics of beta-lactam antibiotics. Scand J Infect Dis Suppl. 1984;42:83–98.PubMed
37.
go back to reference Sweetman SC, Pharm B, Pharms FR. Antibacterials. In: Sweetman SC, Pharm B, Pharms FR, editors. Martindale: the complete drug reference (ISBN 978 0 85369 840 1). London: Pharmaceuticale Press; 2009. p. 204–5, 222, 228–30, 269, 315–6. Sweetman SC, Pharm B, Pharms FR. Antibacterials. In: Sweetman SC, Pharm B, Pharms FR, editors. Martindale: the complete drug reference (ISBN 978 0 85369 840 1). London: Pharmaceuticale Press; 2009. p. 204–5, 222, 228–30, 269, 315–6.
39.
go back to reference Isla A, Trocóniz IF, de Tejada IL, Vázquez S, Canut A, López JM, et al. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol. 2012;68:735–45.CrossRef Isla A, Trocóniz IF, de Tejada IL, Vázquez S, Canut A, López JM, et al. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol. 2012;68:735–45.CrossRef
40.
go back to reference Moine P, Fish DN. Pharmacodynamic modelling of intravenous antibiotic prophylaxis in elective colorectal surgery. Int J Antimicrob Agents. 2013;41:167–73.CrossRef Moine P, Fish DN. Pharmacodynamic modelling of intravenous antibiotic prophylaxis in elective colorectal surgery. Int J Antimicrob Agents. 2013;41:167–73.CrossRef
41.
go back to reference Leng X, Zhao Y, Qiu H, Cao Y, Zhu W, Shen J, et al. Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study. J Antimicrob Chemother. 2014;69:3379–86.CrossRef Leng X, Zhao Y, Qiu H, Cao Y, Zhu W, Shen J, et al. Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China: a multicentre, randomized, double-blind, active-controlled study. J Antimicrob Chemother. 2014;69:3379–86.CrossRef
42.
go back to reference Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63.CrossRef Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63.CrossRef
43.
go back to reference Chen X, Brathwaite CEM, Barkan A, Hall K, Chu G, Cherasard P, et al. Optimal cefazolin prophylactic dosing for bariatric surgery: no need for higher doses or intraoperative redosing. Obes Surg. 2017;27:626–9.CrossRef Chen X, Brathwaite CEM, Barkan A, Hall K, Chu G, Cherasard P, et al. Optimal cefazolin prophylactic dosing for bariatric surgery: no need for higher doses or intraoperative redosing. Obes Surg. 2017;27:626–9.CrossRef
44.
go back to reference Peppard WJ, Eberle DG, Kugler NW, Mabrey DM, Weigelt JA. Association between pre-operative cefazolin dose and surgical site infection in obese patients. Surg Infect (Larchmt). 2017;18:485–90.CrossRef Peppard WJ, Eberle DG, Kugler NW, Mabrey DM, Weigelt JA. Association between pre-operative cefazolin dose and surgical site infection in obese patients. Surg Infect (Larchmt). 2017;18:485–90.CrossRef
45.
go back to reference Ahmadzia HK, Patel EM, Joshi D, Liao C, Witter F, Heine RP, et al. Obstetric surgical site infections: 2 grams compared with 3 grams of cefazolin in morbidly obese women. Obstet Gynecol. 2015;126:708–15.CrossRef Ahmadzia HK, Patel EM, Joshi D, Liao C, Witter F, Heine RP, et al. Obstetric surgical site infections: 2 grams compared with 3 grams of cefazolin in morbidly obese women. Obstet Gynecol. 2015;126:708–15.CrossRef
46.
go back to reference Trent Magruder J, Grimm JC, Dungan SP, Shah AS, Crow JR, Shoulders BR, et al. Continuous intraoperative cefazolin infusion may reduce surgical site infections during cardiac surgical procedures: a propensity-matched analysis. J Cardiothorac Vasc Anesth. 2015;29:1582–7.CrossRef Trent Magruder J, Grimm JC, Dungan SP, Shah AS, Crow JR, Shoulders BR, et al. Continuous intraoperative cefazolin infusion may reduce surgical site infections during cardiac surgical procedures: a propensity-matched analysis. J Cardiothorac Vasc Anesth. 2015;29:1582–7.CrossRef
47.
go back to reference European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMA). ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals: joint interagency antimicrobial consumption and resistance analysis (JIACRA) report. EFSA J. 2017. http://doi.wiley.com/10.2903/j.efsa.2017.4872. European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMA). ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals: joint interagency antimicrobial consumption and resistance analysis (JIACRA) report. EFSA J. 2017. http://​doi.​wiley.​com/​10.​2903/​j.​efsa.​2017.​4872.
48.
go back to reference Zelenitsky SA, Ariano RE, Harding GKM, Silverman RE. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. Antimicrob Agents Chemother. 2002;46:3026–30.CrossRef Zelenitsky SA, Ariano RE, Harding GKM, Silverman RE. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. Antimicrob Agents Chemother. 2002;46:3026–30.CrossRef
Metadata
Title
Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens
Authors
XiangQing Song
MingHui Long
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2018
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0720-y

Other articles of this Issue 5/2018

International Journal of Clinical Pharmacy 5/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.